



**Supplementary Fig. S5. BEBT-908-induced MHC I expression and pro-inflammatory microenvironment in treated tumors.**

(A) Gene set enrichment analysis (GSEA) of IFN $\gamma$  response genes in BEBT-908 treated Daudi cells compared with those in control cells.

(B) Quantitative RT-PCR (qRT-PCR) data showing the expression of interferon gamma signaling pathway related genes in Ctrl., SAHA+GDC-0941, and BEBT-908 treated Daudi cancer cells at dose of indicated IC<sub>50</sub> on day 3.

(C-D) qRT-PCR data showing the expression of HLA-A (C), TAP1 (D) in Ctrl., SAHA+GDC-0941, and BEBT-908 treated Daudi cancer cells at dose of indicated IC<sub>50</sub> on day 3.

(E) Flow-cytometry analysis showing H-2K<sup>b</sup>/H-2D<sup>b</sup> levels on the surface of control and 8 nM BEBT-908 treated MC38 cells on day 1.

(F) FACS analysis of H2-K<sup>b</sup>/H-2D<sup>b</sup> expression on the surface of Ctrl. and BEBT-908 treated MC38 cells in cell culture condition on day 1 after treatment.

(G) FACS analysis of PD-L1 expression on the surface of control and 8 nM BEBT-908 treated MC38 cells on day 1.

(H) FACS analysis of PD-L1 expression of MC38 xenograft tumors treated with control and 100 mg/kg BEBT-908 on day 12.

(I-J) FACS analysis of HLA-A expression on the surface of Ctrl., BEBT-908, and ferroptosis inhibitor (Ferr-1) treated HCT116 (G), Daudi (H) cells at dose of indicated IC<sub>50</sub> on day 1 after treatment.